CD Diagnostics is a fully integrated diagnostics company focused on developing immunoassays that improve patient outcomes. Strengths include immunoassay development, biomarker research, patented technology, and cGMP manufacturing. The company holds strong patents on biomarker diagnostics for orthopedic applications and currently offers seven unique tests in laboratory and point of care formats. Its first product, Synovasure® PJI, is a joint infection test available as a laboratory developed test in the US, and CE marked in both ELISA plate and lateral flow formats in Europe. Synovasure® PJI has revolutionized the orthopedic market with its ease of use, rapid time to result,, and superior performance over current diagnostics (98% sensitive and 98% specific in comparison to current Gold Standard; a multi-test algorithm established by the Musculoskeletal Infection Society). Citrano Medical Laboratories is a CLIA certified facility and subsidiary of CD Diagnostics. CML is a key component in the company’s commercialization strategy, as it allows CD Diagnostics to rapidly commercialize products with established automated systems for result reporting and billing. Research on the Synovasure infection diagnostic test has led to breakthroughs in the areas of sepsis and bacterial meningitis. We are currently seeking partners and funding to develop infection assays for these diseases.
March 2015CD Diagnostics wins "Best Product Innovation of Zimmer in 2014"
February 2015CEO Richard Birkmeyer Speaks at Delaware Bio Breakfast
Clin Orthop Relat Res. 2015 Jan 29. [Epub ahead of print]
Clin Orthop Relat Res. 2014 Oct; 472:3250-3253.